Whether it involves the DEA's much-publicized marijuana rescheduling efforts or MMJ BioPharma's lawful pursuit of a federal registration to conduct FDA-authorized clinical trials, one immovable obstacle remains: the DEA's constitutionally defective administrative adjudication system. Presided over by Chief Administrative Law Judge John J. Mulrooney II, this internal tribunal-often referred to as a "kangaroo court"-violates foundational principles of due process and Article II of the U.S. Constitution.
Read More
N-trans-caffeoyltyramine (NCT) is a natural bioactive compound attracting considerable interest from researchers for its potential role in healthy liver fat metabolism, gut barrier function, and mitochondrial activity.
Using eXoZymes' AI-driven platform, a new and proprietary approach to biomanufacturing of NCT - with all the scale-up advantages of an exozyme biosolution - has been developed: Progressing from concept to lab scale validation with gram-scale production in only 5 months and at a fraction of normal SynBio R&D cost.
NCTx was created as a spin-out company to commercialize the NCT technology and is now able to provide early access partners, under material transfer agreement with product samples. NCTx and eXoZymes are actively looking to increase the number of partners.
Sublingual nano technology delivers 50mg of caffeine rapidly to the body, bringing its unique benefits to the pre-workout market
Read More
All the news about the DEA administrator and Rescheduling marijuana means absolutely nothing if the quota system remains untouched.
Much attention has been given to breaking Ole Miss's monopoly and who becomes the next DEA Administrator. But the real news isn't about who's appointed-it's what the DEA does with the quota system.
Read More
-- David Cory is an industry veteran, bringing more than 30 years of operational experience, in private and public, emerging-stage biotech and large pharma companies with an established track record of building and leading high performing operating teams and financing in the capital markets with over $1B+ raised and multiple company exits by acquisition
-- CID-103 is a potential best in class, anti-CD38 monoclonal antibody, currently dosing in a multi-center Phase 1/2 study in adults with chronic immune thrombocytopenia (ITP); IND submitted to support future clinical trials in adults with renal allograft antibody-mediated rejection (AMR)
Read MoreIcotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor
Filing based on unprecedented data package that met all primary endpoints across four Phase 3 studies, including head-to-head superiority comparisons versus deucravacitinib and evaluation of difficult to treat skin sites
Submission underscores potential to offer moderate-to-severe plaque psoriasis patients the standout combination of complete skin clearance, favorable safety profile, and simplicity of a once-daily pill
Read More
As thousands suffer without access to FDA-approved cannabis treatments, MMJ BioPharma Cultivation is waging a David vs. Goliath legal war against the DEA's decade-long deception-and incoming Administrator Terrance Cole must decide whether to continue the cover-up or finally put patients over politics.
Read MoreNew data shows Telomir-1 fully reverses STAT1 gene silencing by DNA methylation - a key immune regulator suppressed in cancer - delivering stronger epigenetic effects than Paclitaxel or Rapamycin in aggressive PC3 tumor models.
Read More
Full Interview with MMJ CEO Duane Boise to Air Today @ 9.am ET on Cannabis Coast to Coast News.
Terrance Cole, the nominee for DEA Administrator, must confront this DEA rot head on. The agency's marijuana program is a train wreck. The public deserves answers. And legitimate companies like MMJ BioPharma Cultivation deserve justice.
Boise's growing prominence in advanced urologic care was highlighted recently when Dr. Austen Slade welcomed visiting physicians from Stanford University and the University of Washington to observe and study the HoLEP (Holmium Laser Enucleation of the Prostate) procedure under his guidance.
Read More
WHERE IS DEA'S DEPUTY THOMAS PREVOZNIK HIDING?
Bright Green Corp: The DEA-Enabled Stock Market Swindle Files For Bankruptcy.
"Terrance Cole, the nominee for DEA Administrator, must confront this DEA rot head on. The agency's marijuana program is a train wreck. The public deserves answers. And legitimate companies like MMJ BioPharma deserve justice." stated Duane Boise, CEO MMJ.
Read More
A double board-certified foot and ankle surgeon with expertise in trauma, sports injuries, and complex reconstructive procedures, Dr. Ali will expand access to comprehensive podiatric care in the growing Acworth community.
Read More
While Patients Suffer, DEA Manipulates Due Process to Cover Its Cannabis Crimes. The DEA blocking federally compliant pharmaceutical research is not just bureaucratic incompetence; it is systemic negligence bordering on malpractice.
Read More
Partnership established to develop and scale production of ATL-105, a novel recombinant version of alpha-1 antitrypsin
Lead indication is non-CF bronchiectasis; ATL-105 targets disease drivers through a broad multimodal mechanism of action
Mentavi's innovative online asynchronous assessment, validated in a clinical study presented at the 10th World Congress on ADHD, provides clinicians with an efficient, comprehensive diagnostic mental health evaluation at an affordable price for their patients.
Read More
While busting cartels, DEA continues war on science and suffering patients. Duane Boise, CEO of MMJ International Holdings, expressed frustration over the contrasting approaches of federal agencies, stating, "While the FDA is facilitating medical innovation, the DEA's hindrance not only blocks scientific progress but also contradicts directives aimed at revitalizing domestic manufacturing." This situation starkly contrasts with the "Buy American" initiative endorsed by President Trump, which was intended to strengthen U.S. drug production capabilities and reduce dependence on foreign manufacturers.
Jeff Clark's Final Vision 2025 reveals expert-vetted tech stock picks in AI, biotech, and quantum computing-built on proven options strategies, chaos pattern analysis, and actionable investment timelines for serious traders seeking growth in a volatile market.
Read More
A Groundbreaking 28-Day Brain Health Plan from Dr. Will Mitchell Uses Coconut Oil, B Vitamins, and Science-Backed Nutrition to Help Adults Over 45 Combat Memory Decline, Restore Mental Clarity, and Build Long-Term Cognitive Resilience in 2025
Read More
